NOTE! This site uses cookies and similar technologies.

If you not change browser settings, you agree to it. Learn more

I understand

14th Meet The Professor

Advanced International Breast Cancer Course (AIBCC)

Padua (I), September 20th - 22nd 2018



Save the Date

  • Aims
  • Awards & Fellowships
  • Directors
  • Scientific Committee
  • Preliminary Program
  • Slide Kit

Breast cancer represents the front runner in cancer research in many aspects. First, this is a common, chronic and lethal disease where medical interventions are successfully inducing a continuous decline in mortality in spite of increasing incidence. Second, biology drives the entire diagnostic-therapeutic work up of these patients. This is why, nowadays, a breast multidisciplinary team should also include pathologists, molecular biologists, oncogeneticists besides the “classic” clinical specialties. Third, many highly effective interventions are available for each step of the diagnostic and therapeutic work-up of these patients. The increased complexity of the disease, the availability of multiple effective choices and the high expectations of our patients are raising the bar of clinical excellence in this field.
With this goal in mind, the Programme of this international Conference includes lectures on molecular characterization, updated treatments of early and advanced disease, management of difficult cases and hereditary syndromes.
Clinical case discussions and debates are planned to allow a continuous and fruitful exchange of experiences and opinions between speakers and participants.
This 14th Breast Cancer Conference includes a highly qualified international faculty, but will maintain its characteristics of a friendly forum where international opinion leaders and attendees will exchange experiences and share the most exiting advances.
In order to reward scientific excellence and to foster international cooperation, the International Scientific Committee of the 14th AIBCC will award the 8th International Prize for Breast Cancer Research to a scientist who has published a breakthrough paper in the previous year.
We welcome medical oncologists, pathologists, breast surgeons, radiation oncologists and basic scientists to listen to breast cancer leaders and to exchange experiences in a friendly atmosphere.

Addressed to

Gynaecologists and obstetrics, medical oncologists, pathologists, radiologists, radiation oncologists, surgeons. Biologists and nurses.

Official Language

The official language of the Meeting is English. No simultaneous translation will be provided.

CME

Based on the in force regulations approved by the CNFC, Accademia Nazionale di Medicina (provider n. 31) will request the MCE Accreditation.

The credit certification is subject to:

  • attendance at 90% of the Meeting
  • the completion of the Meeting evaluation form
  • the completion of the final questionnaire (at least 75% of correct answers)

We would like to remind you to participants that only 1/3 of CME credits acquired during the years 2017/2019 can come from a sponsorship.

UNIVERSITY OF PADUA AWARD FOR ADVANCES IN BREAST CANCER 2018

The Scientific Committee will select young researchers (< 40 years from any country) who have published in an international peer-reviewed journal, as the principal author, a manuscript reporting important clinical or biological advances in breast cancer. The winner will be invited to present his/her study during the annual Conference.

POSTER SESSION

Participants can send one or more abstracts.

The form should be filled out by following specific guidelines:

  • Use the capitol letter for the title
  • Indicate each author's affiliation (that should include institution, department and town)
  • Underline the designated presenting author’s name.
  • Use font Times New Roman 10, single line spacing.

Abstracts will be selected by the Scientific Committee and will be shown during the poster session on September 22nd from 8 am. Poster size: 70 (wide) x 100 (high).

People sending the selected abstracts will have free registration, dinners and accommodation as well as a reimbursement of travel expenses (max of travel reimbursement € 200,00 for Italian participants and € 300,00 for European participants).

Abstracts should be sent within July 1st. A confirmation will be sent by email within July 20th.

Download Form

Foto

Pier Franco Conte

Division of Medical Oncology 2

Istituto Oncologico Veneto IRCCS
Department of Surgery, Oncology
and Gastroenterology
University of Padua (I)

Foto

Gabriel N. Hortobagyi

Department of Breast Medical Oncology

The University of Texas - MD Anderson Cancer Center
Houston (USA)

Hesham Ahmed Gaballah Elghazaly

Department of Clinical Oncology and nuclear medicine
University of Ainshams
Cairo (EG)

Valentina Guarneri

Division of Medical Oncology 2
Istituto Oncologico Veneto IRCCS
Department of Surgery, Oncology and Gastroenterology
University of Padua (I)

Jacek Jassem

Department of Oncology and Radiotherapy
Medical University of Gdansk (PL)

Stephen Johnston

NIHR Biomedical Research Centre for Cancer
Royal Marsden NHS Foundation Trust & Institute of Cancer Research
London (UK)

Sibylle Loibl

German Breast Group
Department of Medicine and Research
University of Frankfurt (D)

Miguel Martin

Medical Oncology Service
Hospital Universitario Gregorio Marañon
Madrid (E)

Stefania Migliuolo

Europa Donna Italia
Milan (I)

Fedro Alessandro Peccatori

Department of Medical Oncology
European Institute of Oncology (IEO)
Milan (I)

Philip Poortmans

President of ESTRO; President-Elect of ECCO
Department of Radiation Oncology
Institut Curie
Paris (F)

Aleix Prat

Institute of Oncology (VHIO)
Vall d’Hebron- Institute of Oncology
Barcellona (E)

Preliminary Program

Thursday, September 20th

8.30

Registration

9.15

Introduction to the Conference
Pier Franco Conte, Gabriel N. Hortobagyi

 

SESSION I - EVOLUTION IN BREAST CANCER PREVENTION

9.30

Population screening vs risk-adapted surveillance

9.50

9.50 Pharmacological prevention: how and whom?

10.10

A look into the future: multigene panels

10.30

Q&A

10.45

Coffee break

 

SESSION II - LOCOREGIONAL TREATMENT

11.15

Evolution in surgical management of the axilla

11.45

Do margins still matter for in situ and invasive lesions?

12.15

Radiation therapy: what is the real target to aim at

12.45

Q&A

13.00

Lunch

14.00

Multidisciplinary Tumor Board 1 – Locoregional treatment

  • Case 1: Locoregional relapse (questions: locoregional treatment with or without radiosensitisers (drugs; hyperthermia; EF)? “adjuvant” systemic treatment?)
  • Case 2: Breast cancer in a patient previously treated with RT for Hodgkin disease (questions: locoregional treatment? contralateral mastectomy?)
  • Case 3: Healthy patient with familial history asking for risk-reducing mastectomy
  • Conclusive statements

 

SESSION III – SUPPORTIVE AND COMPLEMENTARY THERAPIES

15.00

Diet: myths and facts

15.20

Complementary therapies

15.40

Scalp cooling

16.00

Q&A

10.20

Coffee break

 

SESSION IV – LONG TERM CONSEQUENCES OF SYSTEMIC TREATMENTS

16.40

Gynecologic

17.00

Cardiovascular and metabolic

17.20

Bone health

17.40

Cognitive consequences

18.00

Q&A

18.20

Adjourn

Friday, September 21st

 

SESSION V – PATHOLOGY, GENOMICS & MOLECULAR BIOLOGY

9.00

HER2 testing guidelines: new ASCO/CAP 2018

9.20

Molecular stratification of HER2+ and TNBC

9.40

Lobular breast cancer: a separate entity?

10.00

Q&A

10.20

Coffee Break

 

SESSION VI – NEW PATHWAYS AND NEW DRUGS

10.50

Insights in resistance to CDK4/6 inhibitors

11.10

Targeting the immune system: hopes and hypes

11.30

Combining radiotherapy and immunotherapy

11.50

New promising agents

12.10

Q&A

12.30

Lunch

 

SESSION VII – SYSTEMIC TREATMENTS FOR EARLY BREAST CANCER

14.00

Extended adjuvant endocrine therapy: why? for whom? with what?

14.30

Risk adapted adjuvant treatment for HER2+

15.00

Most promising ongoing trials in early disease

15.30

Q&A

16.00

Multidisciplinary Tumor Board 2 – Challenging cases for pathologists and clinicians (early breast cancer)

  • Case 1: Rare histologies (suggestion: pleomorphic lobular carcinoma, low aggressive triplem negative histologies, micropapillary eyc)
  • Case 2: HER2+ (de-escalated treatment for HER2+ disease)
  • Case 3: Management of non pCR after complete neoadjuvant chemotherapy
  • Conclusive statements

17.00

Adjourn

18.30

Ceremony for the presentation of the University of Padua Award for Advances in Breast Cancer 2018 and best poster award

18.40

Lecture of the Awardee

20.00

Cocktail

20.00

Adjourn

Saturday, September 22nd

 

SESSION VIII – ABC PATIENTS

9.00

New therapeutic algorithms
HR+ ABC
HER2+ ABC
TN ABC

10.30

Q&A

10.45

Coffee break

16.00

Multidisciplinary Tumor Board 3 – Management of Advanced Breast Cancer

  • Case 1: Bone disease
  • Case 2: Brain mets
  • Case 3: Fulminat visceral disease
  • Case 4: Oligometastatic disease
  • Conclusive statements

12.45

Adjourn and final evaluation questionnaire

The slides of the 2017 meeting are now available.

Click here

Send Abstract

Fill out the form by entering the required information and the password that was provided to you (click here to request it). Select the file of your abstract to attach it. ATTENTION: the only accepted format is Adobe PDF. The maximum file size is 2 MB.

Press "Send" to complete the operation.

Your first name(*)
Valore non valido

You last name(*)
Valore non valido

Your E-Mail(*)
Valore non valido

Your Phone #(*)
Valore non valido. Inserire SOLO numeri.

Select your file(*)
Valore non valido o estensione file non permessa

Password(*)
Valore non valido

(*)
Devi dare il consenso al trattamento dei dati o il messaggio non potrà essere spedito!

Click to submit your abstract

Meeting Venue

Centro Convegni Papa Luciani, Via Forcellini 171, Padova.